INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Dec 31, 2020 |
Director, President & CEO
Trans History: 404
|
Director, President & CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 620,270 | -- | 620,270 |
| Dec 31, 2020 |
Director, President and Chief Scientific
Trans History: 628
|
Director, President and Chief Scientific | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 620,270 | -- | 620,270 |
| Dec 03, 2009 |
Director, EVP CSO & Pres Regn Res Labs
Trans History: 628
|
Director, EVP CSO & Pres Regn Res Labs | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 22,397 | $19.29 | 620,375 |
| Mar 10, 2020 |
Director, President and Chief Scientific
Trans History: 628
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 5,099 | $464.59 | 620,576 |
| May 12, 2020 |
Director, President & CEO
Trans History: 404
|
Director, President & CEO | Form 4 | Open market or private sale of non-derivative or derivative security | 2,329 | $557.51 | 623,092 |
| May 11, 2020 |
Director, President & CEO
Trans History: 404
|
Director, President & CEO | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 96,947 | $571.43 | 625,421 |
| Mar 10, 2020 |
Director, President and Chief Scientific
Trans History: 628
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 5,463 | $463.54 | 625,675 |
| Mar 10, 2020 |
Director, President and Chief Scientific
Trans History: 628
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 3,317 | $462.43 | 631,138 |
| Mar 10, 2020 |
Director, President and Chief Scientific
Trans History: 628
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 1,159 | $461.79 | 634,455 |
| Mar 09, 2020 |
Director, President and Chief Scientific
Trans History: 628
|
Director, President and Chief Scientific | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 78,376 | $476.42 | 635,614 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.